DC
MRTX

Diametric Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Diametric Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,916
Closed -$383K – 155
2019
Q3 		$383K Buy
+4,916
New +$461K 0.32% 78

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Diametric Capital's MRTX Position: Q4 2019 in Review

Diametric Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2019, closing a stake of 4,916 shares — an estimated $383K sold.

Diametric Capital first reported a position in MRTX in Q3 2019 and held it in 1 quarter. The position peaked at $383K in Q3 2019. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

  • Diametric Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Diametric Capital sold 4,916 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $383K.
  • Diametric Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Diametric Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $383K in Q3 2019.
  • 190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Diametric Capital's 13F filing for Q4 2019, filed 14 Feb 2020.